Mazdutide Compared to Dulaglutide in Chinese Type 2 Diabetes Patients
TL;DR
A phase 3 study in Chinese adults with type 2 diabetes found that mazdutide, a dual glucagon and GLP-1 receptor agonist, was more effective than dulaglutide in reducing HbA1c and body weight over 28 weeks, with manageable gastrointestinal side effects.
Topics:businesshealth#clinical-trial#dulaglutide#glucagon-like-peptide-1#health#mazdutide#type-2-diabetes
Want the full story? Read the original reporting
Read on Nature